article = {CROGR-2020-3-104}
title = {Palbociclib and Exemestane are Active in Pretreated Low-Grade Serous Ovarian Cancer}
journal = {Case Reports in Obstetrics Gynecology and Reproductive}
year = {2020}
issn = {2674-5070}
doi = {http://dx.doi.org/10.31487/j.CROGR.2020.03.04}
url = {https://www.sciencerepository.org/palbociclib-and-exemestane-are-active-in-pretreated-low-grade-serous_CROGR-2020-3-104 
author = {Gesa  Isensee,Beat  Thürlimann,}
keywords = { Low-grade serous ovarian cancer, CDK4/6-inhibitor, c-MYC amplification, RAS-mutation}
abstract ={We describe a case of a 55-year-old woman with a rare metastatic micropapillary low-grade serous ovarian
cancer who had been heavily pretreated. A KRAS-mutation and c-MYC-amplification were detected, and
we initiated a therapy with the CDK4/6- inhibitor Palbociclib in combination with the steroidal aromatase
inhibitor exemestane. We postulated that the combination therapy leads to a blocking of the c-MYCamplification-activated cell cycle, proliferation, and inhibition of apoptosis, further enhanced by other
oncogenes like mutated RAS. This therapy showed a good and lasting response representing a new
opportunity for therapy in heavily pretreated metastatic micropapillary low-grade serous ovarian cancer.}